ABSTRACT
Objective/Research Question: To compare the safety and efficacy of an aromatase inhibitor (AI), anastrozole, with those of tamoxifen alone and the combination of anastrozole plus tamoxifen for 5 years, as adjuvant treatment in postmenopausal women with early, operable, hormone receptor–positive breast cancer.
